What BML Capital Management, LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1616824 · Filed Aug 7, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 7M |
| −1.5% |
| $32.3M |
| 18.4% |
ENGNenGene Therapeutics Inc. | 6.7M | New | $11.5M | 6.6% |
KHCKraft Heinz Co | 465K | +272.0% | $11M | 6.2% |
OMOutset Medical, Inc. | 2.5M | +32.5% | $10.9M | 6.2% |
KMXCarMax Inc | 172.5K | +11.3% | $9.1M | 5.2% |
TLYSTilly's, Inc. | 2.2M | ±0% | $9M | 5.1% |
PMVPPMV Pharmaceuticals, Inc. | 5.3M | +0.2% | $7.1M | 4.1% |
TILInstil Bio, Inc. | 645.6K | ±0% | $5M | 2.8% |
TGTTarget Corp | 37.5K | ±0% | $4.9M | 2.8% |
ORMPOramed Pharmaceuticals Inc. | 866.3K | −72.6% | $4.2M | 2.4% |
JANXJanux Therapeutics, Inc. | 155K | ±0% | $2.4M | 1.4% |
PLRXPliant Therapeutics, Inc. | 1.5M | ±0% | $1.8M | 1% |
CNTBConnect Biopharma Holdings Ltd | 573.3K | +40.2% | $1.4M | 0.8% |
IMAImageneBio, Inc. | 200.7K | ±0% | $1.2M | 0.7% |
| 335 | New | $386.1K | 0.2% |
| 800 | New | $298K | 0.2% |
| 375 | New | $270K | 0.2% |
